Recent share performance and business mix

Healthpeak Properties (DOC) has seen mixed share performance recently, with a 1.5% gain over the past day, flat movement over the past week, a small rise over the past month, and a 4.8% decline over the past 3 months.

The company, valued at about US$11.45b based on its recent share price of US$16.42, operates as a healthcare focused REIT with a diversified portfolio across outpatient medical, lab, continuing care retirement communities, and other related investments.

Healthpeak reports total revenue of US$2.82b, generated entirely in the United States. Its portfolio includes 703 properties at the last reported date, spanning outpatient medical, lab, CCRC, and other non reportable segments held directly or through joint ventures.

By business line, outpatient medical properties contribute US$1.27b of revenue, lab assets US$860.02m, senior housing US$603.99m, with the balance coming from other non reportable operations and unallocated interest income and other sources.

Net income is reported at US$70.51m, and both revenue and net income show positive annual growth rates based on the latest data provided. This gives investors a reference point for how earnings relate to the size of the portfolio and market value.

Putting the recent moves in context, Healthpeak Properties' year to date share price return of 1.36% contrasts with a 1 year total shareholder return of a 1.12% decline. This suggests momentum has been soft, while income and reinvested distributions have only partly cushioned price weakness.

If this healthcare focused REIT has you thinking about where else capital could work, it may be worth scanning for other real estate and infrastructure plays through 35 power grid technology and infrastructure stocks

With Healthpeak trading around US$16.42 and sitting at a reported discount to some valuation and analyst benchmarks, the key question is whether the current price reflects a bargain or if the market already factors in future growth.

Most Popular Narrative: 18.6% Undervalued

Against the last close at $16.42, the most followed narrative puts Healthpeak Properties' fair value at about $20.17, implying meaningful upside if those assumptions play out.

Ongoing, multi year demographic tailwinds from an aging U.S. population are increasing demand for senior housing and independent living facilities (like Healthpeak's CCRC portfolio), supporting higher occupancy and growing entrance fees, which directly contribute to revenue and operating earnings growth.

Curious what is baked into that fair value? The narrative leans on steady top line expansion, margin improvement, and a valuation multiple that assumes investors keep paying up.

Result: Fair Value of $20.17 (UNDERVALUED)

However, there are still meaningful risks, including pressure on lab tenants with weaker funding and higher capital needs for older assets, that could challenge this upside narrative.

Next Steps

With both risks and rewards in play, the story so far is mixed. Move quickly, review the numbers for yourself, and weigh up the 3 key rewards and 4 important warning signs

Looking for more investment ideas?

If you stop with just one stock, you risk missing other opportunities that fit your goals, so broaden your watchlist now while the data is fresh.

• Target stronger income potential by reviewing companies that yield above 5% with the help of 12 dividend fortresses.
• Hunt for quality at a reasonable price by scanning companies that look attractively priced using the 52 high quality undervalued stocks.
• Prioritise resilience by focusing on companies with healthier finances through the solid balance sheet and fundamentals stocks screener (44 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.